Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma.

Medical hypotheses - 1 Sept 2016

He Yayi, Wang Yan, Zhang Shijia, Ren Shengxiang, Li Jiayu, Zhou Caicun

Abstract excerpt

Lung cancer is the leading cause of cancer related death worldwide and most of lung cancer patients have had metastases when they are diagnosed. With respect to chemotherapy, target therapy is a more effective and less toxic treatments. The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, are one of the representatives of targeted therapy which have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to ErbB Receptors
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Neoplasms

Share to Models, Theoretical

Share to Neoplasm Metastasis

Share to Predictive Value of Tests

Source

Identifiers

PMID: 27515192
DOI: 10.1016/j.mehy.2016.06.009

Genes

EGFR
HGF
MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma.PMID 27515192Read ↗

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.Semantic proximity Read ↗

Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.Semantic proximity Read ↗

Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study.Semantic proximity Read ↗

The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer.Semantic proximity Read ↗

Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.Semantic proximity Read ↗

Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.Semantic proximity Read ↗

Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.Semantic proximity Read ↗

Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients.Semantic proximity Read ↗

EGFR‐TKIs plus local therapy demonstrated survival benefit than EGFR‐TKIs alone in EGFR‐mutant NSCLC patients with oligometastatic or oligoprogressive liver metastasesSemantic proximity Read ↗

Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.Semantic proximity Read ↗

Metastatic Lung Tumors from Colorectal Cancer with EGFR Mutations That Responded to Osimertinib.Semantic proximity Read ↗

Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.